Phase I trial of temozolomide plus O(6)-benzylguanine 5-day regimen with recurrent malignant glioma

This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG). Both TMZ...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Quinn, Jennifer A., Jiang, Sara Xiaoyin, Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Rich, Jeremy N., Gururangan, Sridharan, Friedman, Allan H., Bigner, Darell D., Sampson, John H., McLendon, Roger E., Herndon, James E., Walker, Amy, Friedman, Henry S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Duke University Press 2009
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2765345/
https://ncbi.nlm.nih.gov/pubmed/19289491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2009-007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi